Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 3 2Phase 1/2 1

Status

Completed 4Withdrawn 1Unknown 1

Sponsor Class

NIH 24OTHER 8INDUSTRY 6NETWORK 1

Study Type

Interventional 6

Sponsor

Cancer Type

Other hematologic neoplasm 2Dermatologic 2Tumor-Agnostic 1Other solid neoplasm 1Lymphoid 1

Conditions

Neoplasms 2Melanoma 2Solid Tumors 1Skin Neoplasms 1Leukemia, Lymphoid 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Bronchiolitis Obliterans Syndrome 1

Interventions

pembrolizumab 1029Carboplatin 966Paclitaxel 941Gemcitabine 798Cisplatin 754Docetaxel 697Bevacizumab 638Nivolumab 519Pemetrexed 507Capecitabine 475Cyclophosphamide 468Fluorouracil 424Dexamethasone 409Rituximab 391Oxaliplatin 351Injections 344Trastuzumab 313atezolizumab 311Cetuximab 291Leucovorin 288Irinotecan 269130-nm albumin-bound paclitaxel 255Prednisone 250Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 215durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
INDUSTRY × oblimersen × Clear all
NCT00636545 2012-04-06

Genasense as a 2-hour Intravenous Infusion in Subjects With Solid Tumors

Genta Incorporated

Phase 1 Completed
25 enrolled
Other solid neoplasm

Solid Tumors

NCT00409383 2011-11-07

Abraxane and Temodar Plus Genasense in Advanced Melanoma

Genta Incorporated

Phase 1 Unknown
28 enrolled
Dermatologic

Melanoma

NCT00518895 2011-11-07

AGENDA

Genta Incorporated

Phase 3 Completed
300 enrolled
Dermatologic

Melanoma, Skin Neoplasms

NCT00021749 2009-11-13

Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia

Genta Incorporated

Phase 1/2 Completed
40 enrolled
LymphoidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00517218 2008-02-11

This Study is Being Performed to Evaluate the Effect of Genasense on the Efficacy and the Safety of Rituximab/Fludarabine Combination Treatment in Previously Untreated Subjects With Chronic Lymphocyctic Leukemia(CLL)

Genta Incorporated

Phase 3 Withdrawn
Other hematologic neoplasm

Leukemia, Lymphoid

NCT00543231 2007-10-12

A Phase I Study of G3139 Subcutaneous in Solid Tumors

Genta Incorporated

Phase 1 Completed
8 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡